Nomination Committee for the 2018 Annual General Meeting in PledPharma AB
October 25, 2017
PledPharma AB Company Announcement Nomination Committee for the 2018 Annual General Meeting in PledPharma AB The Chairman of PledPharma AB has established a Nomination Committee for the Annual General Meeting that is to be held on April 24, 2018. The Nomination Committee is composed of members appointed by the four largest shareholders in terms of voting rights, that have accepted the invitation to participate in the committee. The following members have been appointed by the four largest shareholders that have accepted the invitation to participate in the Nomination Committee: Nortal Investments AB and Zimbrine Holding B.V.: Staffan Persson Berinor B.V.: Peter Lindell Flerie Participation AB: Thomas Eldered Handelsbanken Fonder: Astrid Samuelsson In total, the Nomination Committee represents 39,35% of the total number of shares and votes in the company. The Nomination Committee has elected Staffan Persson as chairman for the Committee. Håkan Åström (Chairman of PledPharma) has been co-opted to the Nomination Committee. The Committee's assignment is to present to the Annual General Meeting proposals regarding Chairman and other members of the board as well as remuneration to the Board´s members. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals to the process to appoint the Nomination Committee for the AGM in 2019. Shareholders who wish to submit proposals to the Nomination Committee can do so by email: [email protected] For more information please contact: Håkan Åström, Chairman, phone: +46 703 747 213 Nicklas Westerholm, CEO, phone: +46 73 354 20 62 About PledPharma PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company's most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A phase IIb study has been conducted and will serve as the basis for the continued development. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 80 00). For more information, see www.pledpharma.se
